CONGRESS NEWS

Highlights in acute myeloid leukemia (AML): what is going to change?

SUMMARY

The decision making process in AML integrates clinical features, an increasing amount of genetic information and minimal residual disease (MRD) data. Combining these data aims at answering the following questions:

• do I treat my patient with an intensive (= curative) or a non intensive (= non-curative) approach ?
• do I have therapeutic targets to improve the current treatment?
• is there an indication for a stem cell transplantation (SCT), maintenance therapy, etc.

Each new edition of ASH brings some new answers. This was again the case at the 2016 annual ASH meeting.

(BELG J HEMATOL 2017;8(1):29–33)

Highlights on Myelodysplastic Syndromes (MDS)

SUMMARY

This ASH 2016 report will focus on the diagnostic and prognostic utility of molecular abnormalities and on new treatment modalities in MDS. We selected 7 abstracts dealing with these topics.

(BELG J HEMATOL 2017;8(1):34–7)

Plenary session at ASH 2016

SUMMARY

The plenary session during the 2016 annual meeting of the American Society of Hematology featured six presentation covering different aspects of hematology. These abstracts discussed important innovations in the management of sickle cell disease, follicular lymphoma, hemophilia and ALL. In addition to this two abstracts addressed issues related to hematopoiesis.

(BELG J HEMATOL 2017;8(1):38–40)

Highlights in haematological cancer from the 2016 annual meeting of the American Society of Clinical Oncology (ASCO)

Summary

From June 3^rd till June 6^th, Chicago again formed the background for the biggest cancer congress in the world. Notwithstanding the fact that solid tumours remain the main focus of the annual meeting of the American Society of Clinical Oncology (ASCO), the meeting program also included some interesting lectures on haematological malignancies. The aim of this report is not to discuss all these studies, but will address some of the key presentations on haematological cancer from ASCO 2016. For a more complete overview we would like to refer to the congress website, where all abstracts and a plethora of webcasts can be found.

(BELG J HEMATOL 2016;7(5):203–6)

Highlights in multiple myeloma

Summary

Multiple myeloma (MM) is one of the haematological malignancies with the fastest therapeutic development. Consequently, interesting new data on both preclinical and clinical progress in MM were presented at the 2016 EHA meeting in Copenhagen. We have selected four clinical and one preclinical abstract for discussion in this paper. The choice is based on the importance of the presentations and the impact their results will have on the future treatment landscape in MM.

(BELG J HEMATOL 2016;7(4):130–3)

Exciting times in acute myeloid leukaemia: highlights from EHA 2016

Summary

The state of the art in acute myeloid leukaemia (AML) in 2016 is changing dramatically. This is the result of the availability of new techniques for genome sequencing leading to understanding of the AML ontogeny at the molecular level, redefining minimal residual disease status in daily practice, the optimised use of induction and post-remission strategies and the introduction of many novel agents. Hopefully this will ultimately lead to the long expected improvement in survival for our individual patients.

(BELG J HEMATOL 2016;7(4):137–42)

Highlights in chronic lymphocytic leukaemia & indolent non-Hodgkin lymphoma

(BELG J HEMATOL 2016;7(4):145–8)